TY  - JOUR
AU  - Albanell, J
AU  - Martínez, M T
AU  - Ramos, M
AU  - O'Connor, M
AU  - de la Cruz-Merino, L
AU  - Santaballa, A
AU  - Martinez-Jañez, N
AU  - Moreno, F
AU  - Fernandez, I
AU  - Alarcon, J
AU  - Virizuela, J A
AU  - de la Haba-Rodriguez, J
AU  - Sanchez-Rovira, P
AU  - Gonzalez-Cortijo, L
AU  - Margeli, M
AU  - Sanchez-Muñoz, A
AU  - Anton, A
AU  - Casas, M
AU  - Bezares, S
AU  - Rojo, F
PY  - 2021
DO  - 10.1016/j.ejca.2021.11.010
UR  - http://hdl.handle.net/10668/22170
T2  - European journal of cancer (Oxford, England : 1990)
AB  - The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast cancer (ABC) patients remains...
LA  - en
PB  - Elsevier
KW  - Breast cancer
KW  - CDK 4/6
KW  - Endocrine-sensitive
KW  - First-line
KW  - Fulvestrant
KW  - Metastatic
KW  - Palbociclib
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Breast Neoplasms
KW  - Double-Blind Method
KW  - Female
KW  - Fulvestrant
KW  - Humans
KW  - Middle Aged
KW  - Piperazines
KW  - Pyridines
TI  - Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
TY  - research article
VL  - 161
ER  -